Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential moxifloxacin versus piperacillin/tazobactam followed by amoxicillin/clavulanic acid for complicated skin and skin structure infections
NL-OMON29728Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- May 2007
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of moxifloxacin, piperacillin + tazobactam and amoxicillin + clavulanate in Complicated skin and skin structure infection (cSSSI) (2 arms), sponsored by Bayer. Started May 2007; status: active, not recruiting.
02
Drugs
moxifloxacinpiperacillin + tazobactamamoxicillin + clavulanate
03
Conditions
Complicated skin and skin structure infection (cSSSI)
Beyond the preview
Go deeper on NL-OMON29728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29728.